This study adds to the growing evidence that Alzheimer’s disease may start long before traditional symptoms appear. The fact ...

The University of Texas at Tyler received a $2 million gift from the Byers Family Foundation to help establish a center for ...

Two new medications, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease. These are known as disease-modifying treatments and have been licensed ...

The University of Texas at Tyler has received a generous $2 million donation from the Byers Family Foundation.

A research team has discovered that the two key pathological hallmarks of Alzheimer's -- tau protein and beta-amyloid -- affect brain circuits in distinct yet synergistic ways, particularly those ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

A new study found that older adults with fluctuating cholesterol levels—regardless of how high—could be 60% more likely to ...

A recent Brazilian study published in Nature Cardiovascular Research has highlighted promising pathways for preventing and ...

Groundbreaking study from researchers at The University of Texas Health Science Center at San Antonio uncovers genetic factor that may contribute to the risk of late-onset Alzheimer’s disease, a ...

A paradigm-shifting study from the Centre for Addiction and Mental Health (CAMH) shows an experimental drug, GL-II-73, has the potential to restore memory and cognitive function in a mouse model of ...

New research links gut health to Alzheimer’s, using advanced imaging to reveal structural changes and potential early ...